Effect of use of 13-valent pneumococcal conjugate vacci pneumococcal disease in children and adults in the USA population-based surveillance

Lancet Infectious Diseases, The

15, 301-309

DOI: 10.1016/s1473-3099(14)71081-3

Citation Report

#	Article	IF	Citations
1	Value Added by the Prevnar 13 Childhood Immunization Program in Alberta, Canada (2010â€“2015). Drugs - Real World Outcomes, 2015, 2, 311-318.	0.7	7
2	Streptococcus pneumoniae NanC. Journal of Biological Chemistry, 2015, 290, 27736-27748.	1.6	40
3	Clinical characteristics of the patients with bacteremia due to Moraxella catarrhalis in children: a caseâ€“control study. BMC Infectious Diseases, 2015, 16, 73.	1.3	14
4	Use of Pneumococcal Disease Epidemiology to Set Policy and Prevent Disease during 20 Years of the Emerging Infections Program. Emerging Infectious Diseases, 2015, 21, 1551-1556.	2.0	13
5	Pneumococcal Infection among Children before Introduction of 13-Valent Pneumococcal Conjugate Vaccine, Cambodia. Emerging Infectious Diseases, 2015, 21, 2080-2083.	2.0	19
6	Cultivation of an Adaptive Domestic Network for Surveillance and Evaluation of Emerging Infections. Emerging Infectious Diseases, 2015, 21, 1499-1509.	2.0	10
7	Hostâ€“pathogen interaction during bacterial vaccination. Current Opinion in Immunology, 2015, 36, 1-7.	2.4	21
8	Editorial Commentary: The Story of Sisyphus: Why We Need a Universal Pneumococcal Vaccine to Replace Current Conjugate Vaccines. Clinical Infectious Diseases, 2015, 61, 776-778.	2.9	13
9	Reply to Farkouh RA et al. Comment on â€œCost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-Typeable Haemophilus Influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Childrenâ€• Infectious Diseases and Therapy, 2015, 4, 235-244.	1.8	3
10	In-Hospital Pneumococcal Polysaccharide Vaccination Is Associated With Detection of Pneumococcal Vaccine Serotypes in Adults Hospitalized for Community-Acquired Pneumonia. Open Forum Infectious Diseases, 2015, 2, ofv135.	0.4	9
11	Decision-Making and the Barriers to Judicious Antibiotic Use. Pediatrics, 2015, 136, 387-388.	1.0	4
12	Noninvasive Streptococcus pneumoniae Serotypes Recovered from Hospitalized Adult Patients in the United States in 2009 to 2012. Antimicrobial Agents and Chemotherapy, 2015, 59, 5595-5601.	1.4	24
13	Biographical Feature: James Jorgensen, Ph.D.. Journal of Clinical Microbiology, 2015, 53, 2398-2401.	1.8	2
14	Lessons learned from making and implementing vaccine recommendations in the U.S.. Vaccine, 2015, 33, D78-D82.	1.7	6
16	Lessons Learned From Making and Implementing Vaccine Recommendations in the U.S.. American Journal of Preventive Medicine, 2015, 49, S406-S411.	1.6	10
17	PCV13 in the USA: early successes and potential challenges. Lancet Infectious Diseases, The, 2015, 15, 254-256.	4.6	4
18	Review of Current Pneumococcal Vaccine Guidelines. Current Emergency and Hospital Medicine Reports, 2015, 3, 121-125.	0.6	0
19	First Human Challenge Testing of a Pneumococcal Vaccine. Double-Blind Randomized Controlled Trial. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 853-858.	2.5	81

#	Article	IF	Citations
20	Pneumococcal Capsules and Their Types: Past, Present, and Future. Clinical Microbiology Reviews, 2015, 28, 871-899.	5.7	557
21	Despite High Cost, Improved Pneumococcal Vaccine Expected To Return 10-Year Net Savings Of $12ÂBillion. Health Affairs, 2015, 34, 1234-1240.	2.5	8
22	Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. European Respiratory Journal, 2015, 46, 1407-1416.	3.1	92
23	Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: CAPiTA, the community-acquired pneumonia immunization trial in adults. Human Vaccines and Immunotherapeutics, 2015, 11, 1825-1827.	1.4	17
24	Pneumococcal disease prevention among adults: Strategies for the use of pneumococcal vaccines. Vaccine, 2015, 33, D60-D65.	1.7	89
25	Restraining the pneumococcus. Lancet Infectious Diseases, The, 2015, 15, 491-492.	4.6	2
26	Remembering the Benefits of Vaccination. JAMA Pediatrics, 2015, 169, 624.	3.3	1
27	Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infectious Diseases, The, 2015, 15, 535-543.	4.6	474
28	Assignment of Weight-Based Antibody Units for Seven Additional Serotypes to a Human Pneumococcal Standard Reference Serum, 007sp. Vaccine Journal, 2015, 22, 1154-1159.	3.2	15
29	13-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults. Drugs, 2015, 75, 1535-1546.	4.9	11
30	Mechanisms and impact of genetic recombination in the evolution of Streptococcus pneumoniae. Computational and Structural Biotechnology Journal, 2015, 13, 241-247.	1.9	50
31	The Influence of Influenza and Pneumococcal Vaccines on Community-Acquired Pneumonia (CAP) Outcomes Among Elderly Patients. Current Infectious Disease Reports, 2015, 17, 49.	1.3	5
32	Racial and Regional Differences in Rates of Invasive Pneumococcal Disease. Pediatrics, 2015, 136, e1186-e1194.	1.0	18
33	Direct and indirect effects of the 13-valent pneumococcal conjugate vaccine administered to infants and young children. Future Microbiology, 2015, 10, 1599-1607.	1.0	29
34	The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on serotype 19A invasive pneumococcal disease. Expert Review of Vaccines, 2015, 14, 1359-1366.	2.0	15
35	Pediatric acute osteomyelitis in the postvaccine, methicillin-resistant Staphylococcus aureus era. American Journal of Emergency Medicine, 2015, 33, 1420-1424.	0.7	39
36	Secular trends (1990â€“2013) in serotypes and associated non-susceptibility of S. pneumoniae isolates causing invasive disease in the pre-/post-era of pneumococcal conjugate vaccines in Spanish regions without universal paediatric pneumococcal vaccination. Vaccine, 2015, 33, 5691-5699.	1.7	39
37	The Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA): what is the future of pneumococcal conjugate vaccination in elderly?. Future Microbiology, 2015, 10, 1405-1413.	1.0	12

#	Article	IF	Citations
38	Pneumococcal Disease Prevention Among Adults. American Journal of Preventive Medicine, 2015, 49, S383-S390.	1.6	32
39	Preventing pneumococcal infections in older adults. Lancet Respiratory Medicine,the, 2015, 3, 834-836.	5.2	3
41	Pneumococcal Disease in the Era of Pneumococcal Conjugate Vaccine. Infectious Disease Clinics of North America, 2015, 29, 679-697.	1.9	68
42	Quantitative and Functional Antibody Responses to the 13-Valent Conjugate and/or 23-Valent Purified Polysaccharide Vaccine in Aging HIV-Infected Adults. Journal of AIDS & Clinical Research, 2016, 07, .	0.5	9
43	A Review of Pneumococcal Vaccines: Current Polysaccharide Vaccine Recommendations and Future Protein Antigens. Journal of Pediatric Pharmacology and Therapeutics, 2016, 21, 27-35.	0.3	168
44	Indirect Effects of Pneumococcal Conjugate Vaccines in National Immunization Programs for Children on Adult Pneumococcal Disease. Infection and Chemotherapy, 2016, 48, 257.	1.0	20
45	Early Changes in the Serotype Distribution of Invasive Pneumococcal Isolates from Children after the Introduction of Extended-valent Pneumococcal Conjugate Vaccines in Korea, 2011-2013. Journal of Korean Medical Science, 2016, 31, 1082.	1.1	10
46	A Call for Greater Consideration for the Role of Vaccines in National Strategies to Combat Antibiotic-Resistant Bacteria: Recommendations from the National Vaccine Advisory Committee. Public Health Reports, 2016, 131, 11-16.	1.3	23
47	Serotype 3 Remains the Leading Cause of Invasive Pneumococcal Disease in Adults in Portugal (2012â€“2014) Despite Continued Reductions in Other 13-Valent Conjugate Vaccine Serotypes. Frontiers in Microbiology, 2016, 7, 1616.	1.5	60
48	Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany. PLoS ONE, 2016, 11, e0161257.	1.1	63
49	Population structure of invasive Streptococcus pneumoniae isolates among Alaskan children in the conjugate vaccine era, 2001 to 2013. Diagnostic Microbiology and Infectious Disease, 2016, 86, 224-230.	0.8	6
50	Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Carriage Among American Indians. Pediatric Infectious Disease Journal, 2016, 35, 907-914.	1.1	49
51	Pneumococcal vaccination. Current Opinion in Infectious Diseases, 2016, 29, 187-196.	1.3	34
52	Global Burden of Neonatal Invasive Pneumococcal Disease. Pediatric Infectious Disease Journal, 2016, 35, 172-179.	1.1	11
53	Impact of the 13-valent pneumococcal conjugate vaccine on Streptococcus pneumoniae multiple serotype carriage. Vaccine, 2016, 34, 4072-4078.	1.7	25
54	Complications of Pneumococcal Bacteremia After Thirteen-valent Conjugate Vaccine Withdrawal. Pediatric Infectious Disease Journal, 2016, 35, 1281-1287.	1.1	3
55	Serotypes and genotypes of Streptococcus pneumoniae isolates from Trinidad and Tobago. International Journal of Infectious Diseases, 2016, 46, 100-106.	1.5	19
56	Diagnosis and management of undifferentiated fever in children. Journal of Infection, 2016, 72, S68-S76.	1.7	12

#	Article	IF	Citations
57	Relating Pneumococcal Carriage Among Children to Disease Rates Among Adults Before and After the Introduction of Conjugate Vaccines. American Journal of Epidemiology, 2016, 183, 1055-1062.	1.6	45
58	Vaccines for Healthcare-associated Infections: Promise and Challenge. Clinical Infectious Diseases, 2016, 63, 657-662.	2.9	21
59	Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden. European Respiratory Journal, 2016, 47, 1208-1218.	3.1	125
60	Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective. Clinical Microbiology Reviews, 2016, 29, 525-552.	5.7	240
61	Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine. Clinical Infectious Diseases, 2016, 62, 1119-1125.	2.9	127
62	Insight Into Resistance Phenotypes of Emergent Non 13-valent Pneumococcal Conjugate Vaccine Type Pneumococci Isolated From Invasive Disease After 13-valent Pneumococcal Conjugate Vaccine Implementation in France. Open Forum Infectious Diseases, 2016, 3, ofw020.	0.4	63
63	Should Committees That Write Guidelines and Recommendations Publish Dissenting Opinions?. Mayo Clinic Proceedings, 2016, 91, 634-639.	1.4	6
64	Editorial Commentary: Pneumococcal Vaccination in Adults: Do We Have to Recalculate Our Approach?. Clinical Infectious Diseases, 2016, 62, 1527-1528.	2.9	1
65	The impact of pneumococcal conjugate vaccines on carriage of and disease caused by Streptococcus pneumoniae serotypes 6C and 6D in southern Israel. Vaccine, 2016, 34, 2806-2812.	1.7	13
66	Pneumococcal conjugate vaccine herd effects on non-invasive pneumococcal pneumonia in elderly. Vaccine, 2016, 34, 3275-3282.	1.7	28
67	In Vitro Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States. Antimicrobial Agents and Chemotherapy, 2016, 60, 4407-4411.	1.4	38
68	Immunization Update. Physician Assistant Clinics, 2016, 1, 615-625.	0.1	0
69	Recombination in Streptococcus pneumoniae Lineages Increase with Carriage Duration and Size of the Polysaccharide Capsule. MBio, 2016, 7, .	1.8	50
70	Gram-Positive Diplococci in a Cerebrospinal Fluid Gram Stain. Open Forum Infectious Diseases, 2016, 3, ofw206.	0.4	2
71	Modeling The Economic Burden Of Adult Vaccine-Preventable Diseases In The United States. Health Affairs, 2016, 35, 2124-2132.	2.5	119
72	Conjugated pneumococcal vaccine versus polysaccharide pneumococcal vaccine for prevention of pneumonia and invasive pneumococcal disease in immunocompetent and immunocompromised adults and children. The Cochrane Library, 2016, , .	1.5	2
73	Infant Mouse Model for the Study of Shedding and Transmission during Streptococcus pneumoniae Monoinfection. Infection and Immunity, 2016, 84, 2714-2722.	1.0	59
74	What do we know about the cost-effectiveness of pneumococcal conjugate vaccination in older adults?. Human Vaccines and Immunotherapeutics, 2016, 12, 2666-2669.	1.4	4

#	Article	IF	Citations
75	Penicillin-Binding Protein Transpeptidase Signatures for Tracking and Predicting Î²-Lactam Resistance Levels in Streptococcus pneumoniae. MBio, 2016, 7, .	1.8	151
76	Vaccinations for the Older Adult. Clinics in Geriatric Medicine, 2016, 32, 609-625.	1.0	12
77	Pneumonia hospitalisations in Scotland following the introduction of pneumococcal conjugate vaccination in young children. BMC Infectious Diseases, 2016, 16, 390.	1.3	32
78	Reply to Varghese et al.'s response to Wu et al. â€" â€œCost effectiveness analysis of infant pneumococcal vaccination in Malaysia and Hong Kongâ€• Human Vaccines and Immunotherapeutics, 2016, 12, 2681-2684.	1.4	0
79	A community-based cross-sectional immunisation survey in parents of primary school students. Npj Primary Care Respiratory Medicine, 2016, 26, 16011.	1.1	6
80	Impact of pneumococcal conjugate vaccines on pneumococcal meningitis cases in France between 2001 and 2014: a time series analysis. BMC Medicine, 2016, 14, 211.	2.3	43
81	Persistent Sex Disparities in Invasive Pneumococcal Diseases in the Conjugate Vaccine Era. Journal of Infectious Diseases, 2016, 214, 792-797.	1.9	21
82	How Can Vaccines Contribute to Solving the Antimicrobial Resistance Problem?. MBio, 2016, 7, .	1.8	152
83	Effect of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in The Gambia: a population-based surveillance study. Lancet Infectious Diseases, The, 2016, 16, 703-711.	4.6	156
84	Clinical and Epidemiological Evidence of the Red Queen Hypothesis in Pneumococcal Serotype Dynamics. Clinical Infectious Diseases, 2016, 63, 619-626.	2.9	19
85	Changing Epidemiology of Pneumococcal Disease in the Era of Conjugate Vaccines. Current Epidemiology Reports, 2016, 3, 125-135.	1.1	8
86	Serotype distribution and penicillin-non-susceptibility ofStreptococcus pneumoniaecausing invasive diseases in Kuwait: A 10-year study of impact of pneumococcal conjugate vaccines. Expert Review of Vaccines, 2016, 15, 1337-1345.	2.0	8
87	Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the USA. Clinical Microbiology and Infection, 2016, 22, 60.e9-60.e29.	2.8	161
88	Association of serotype with respiratory presentations of pneumococcal infection, Ontario, Canada, 2003â€“2011. Vaccine, 2016, 34, 846-853.	1.7	12
89	Bacterial Respiratory Infections Complicating Human Immunodeficiency Virus. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 214-229.	0.8	10
90	Childhood Vaccine Exemptions: A Broader Perspective Is Required. Pediatrics, 2016, 137, e20160189.	1.0	6
91	Interim results of an ecological experiment â€" Conjugate vaccination against the pneumococcus and serotype replacement. Human Vaccines and Immunotherapeutics, 2016, 12, 358-374.	1.4	93
92	Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study. Lancet Respiratory Medicine,the, 2016, 4, 399-406.	5.2	144

#	Article	IF	Citations
93	Declining mortality from adult pneumococcal infections linked to children's vaccination. Journal of Infection, 2016, 72, 439-449.	1.7	31
94	Reduction of Streptococcus pneumoniae Colonization and Dissemination by a Nonopsonic Capsular Polysaccharide Antibody. MBio, 2016, 7, e02260-15.	1.8	19
96	Evaluating the impact of PCV-10 on invasive pneumococcal disease in Brazil: A time-series analysis. Human Vaccines and Immunotherapeutics, 2016, 12, 285-292.	1.4	56
97	Capsular Polysaccharide (CPS) Release by Serotype 3 Pneumococcal Strains Reduces the Protective Effect of Anti-Type 3 CPS Antibodies. Vaccine Journal, 2016, 23, 162-167.	3.2	93
98	Pneumococcal conjugate vaccine use in adults. Expert Review of Vaccines, 2016, 15, 279-293.	2.0	18
99	Early Streptococcus pneumoniae serotype changes in Utah adults after the introduction of PCV13 in children. Vaccine, 2016, 34, 474-478.	1.7	17
100	Immunisation schedule of the Spanish Association of Paediatrics: 2016 recommendations. Anales De PediatrÃa (English Edition), 2016, 84, 60.e1-60.e13.	0.1	2
101	The Impact of Prior Antibiotic Therapy on Outcomes in Children Hospitalized for Community-Acquired Pneumonia. Current Infectious Disease Reports, 2016, 18, 3.	1.3	3
102	Why the recent ACIP recommendations regarding conjugate pneumococcal vaccine in adults may be irrelevant. Human Vaccines and Immunotherapeutics, 2016, 12, 331-335.	1.4	23
103	Invasive Pneumococcal Disease Among Immunocompromised Persons: Implications for Vaccination Programs. Clinical Infectious Diseases, 2016, 62, 139-147.	2.9	97
104	Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong. Human Vaccines and Immunotherapeutics, 2016, 12, 403-416.	1.4	31
105	Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany. European Journal of Health Economics, 2017, 18, 273-292.	1.4	18
107	PCV13-vaccinated children still carrying PCV13 additional serotypes show similar carriage density to a control group of PCV7-vaccinated children. Vaccine, 2017, 35, 945-950.	1.7	16
108	Immunogenicity differences of a 15-valent pneumococcal polysaccharide conjugate vaccine (PCV15) based on vaccine dose, route of immunization and mouse strain. Vaccine, 2017, 35, 865-872.	1.7	21
109	Pneumococcal serotype distribution: A snapshot of recent data in pediatric and adult populations around the world. Human Vaccines and Immunotherapeutics, 2017, 13, 1229-1241.	1.4	40
110	Increased long-term mortality after survival of invasive pneumococcal disease: a population-based study. Infectious Diseases, 2017, 49, 365-372.	1.4	5
111	Discovery of Novel Pneumococcal Serotype 35D, a Natural WciG-Deficient Variant of Serotype 35B. Journal of Clinical Microbiology, 2017, 55, 1416-1425.	1.8	68
112	Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae strains isolated in Japan after introduction of the routine immunization program. Journal of Infection and Chemotherapy, 2017, 23, 234-240.	0.8	25

#	Article	IF	Citations
113	The rise and fall of pneumococcal serotypes carried in the PCV era. Vaccine, 2017, 35, 1293-1298.	1.7	68
114	Immunisation schedule of the Spanish Association of Paediatrics: 2017 recommendations. Anales De PediatrÃa (English Edition), 2017, 86, 98.e1-98.e9.	0.1	1
115	PCV13 serotype decrease in Italian adolescents and adults in the post-PCV13 era: Herd protection from children or secular trend?. Vaccine, 2017, 35, 1544-1550.	1.7	9
116	The distribution and annual changes in the Streptococcus pneumoniae serotypes in adult Japanese patients with pneumococcal pneumonia from 2011 to 2015. Journal of Infection and Chemotherapy, 2017, 23, 301-306.	0.8	16
117	Impact of pneumococcal conjugate vaccines for children in high- and nonâ€“high-income countries. Expert Review of Vaccines, 2017, 16, 625-640.	2.0	59
118	A new paradigm in pneumococcal conjugate vaccination: moving from individual to herd protection. International Journal of Infectious Diseases, 2017, 60, 96-97.	1.5	4
119	Update on community-acquired bacterial meningitis: guidance and challenges. Clinical Microbiology and Infection, 2017, 23, 601-606.	2.8	81
120	The epidemiology of invasive pneumococcal disease in older adults in the post-PCV era. Has there been a herd effect?. Epidemiology and Infection, 2017, 145, 2390-2399.	1.0	43
121	Pneumococcal conjugate vaccines in Latin America: are PCV10 and PCV13 similar in terms of protection against serotype 19A?. Expert Review of Vaccines, 2017, 16, 657-660.	2.0	12
122	Invasive Pneumococcal Disease in Patients With Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 2017, 39, 341-344.	0.3	14
123	Pneumococcal conjugate vaccine use in adults â€“ Addressing an unmet medical need for non-bacteremic pneumococcal pneumonia. Vaccine, 2017, 35, 5406-5417.	1.7	27
124	Streptococcus pneumoniae antimicrobial resistance decreased in the Helsinki Metropolitan Area after routine 10-valent pneumococcal conjugate vaccination of infants in Finland. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 2109-2116.	1.3	19
125	Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study. Lancet Respiratory Medicine,the, 2017, 5, 648-656.	5.2	96
126	The future of paediatric pneumococcal conjugate vaccines. Lancet Respiratory Medicine,the, 2017, 5, 605-606.	5.2	1
127	The herd effects of infant PCV7/PCV13 sequential implementation on adult invasive pneumococcal disease, six years post implementation; a nationwide study in Israel. Vaccine, 2017, 35, 2449-2456.	1.7	41
128	Pneumococcal Pneumonia Requiring Hospitalization in US Children in the 13-Valent Pneumococcal Conjugate Vaccine Era. Clinical Infectious Diseases, 2017, 64, 1699-1704.	2.9	85
129	Increased incidence of adult pneumococcal pneumonia during school holiday periods. ERJ Open Research, 2017, 3, 00100-2016.	1.1	3
130	Risk factors for community-acquired bacterial meningitis. Infectious Diseases, 2017, 49, 433-444.	1.4	32

#	Article	IF	Citations
131	Vital Signs: Epidemiology of Sepsis: Prevalence of Health Care Factors and Opportunities for Prevention. Annals of Emergency Medicine, 2017, 69, 131-135.	0.3	1
132	Costâ€Effectiveness of the 4 Pillars Practice Transformation Program to Improve Vaccination of Adults Aged 65 and Older. Journal of the American Geriatrics Society, 2017, 65, 763-768.	1.3	11
133	Update on Pediatric Overuse. Pediatrics, 2017, 139, .	1.0	40
134	Herd effects of child vaccination with pneumococcal conjugate vaccine against pneumococcal non-invasive community-acquired pneumonia: What is the evidence?. Human Vaccines and Immunotherapeutics, 2017, 13, 1177-1181.	1.4	8
135	Trends in pneumococcal meningitis hospitalizations following the introduction of the 13-valent pneumococcal conjugate vaccine in the United States. Vaccine, 2017, 35, 6160-6165.	1.7	18
136	Playing â€œWhack-a-Moleâ€•With Pneumococcal Serotype Eradication. Pediatrics, 2017, 140, .	1.0	4
137	The burden of PCV13 serotypes in hospitalized pneumococcal pneumonia in Spain using a novel urinary antigen detection test. CAPA study. Vaccine, 2017, 35, 5264-5270.	1.7	23
139	Rethinking number-needed-to-vaccinate for pneumococcal conjugate vaccines in older adults: Current and future implications. Vaccine, 2017, 35, 5360-5365.	1.7	9
140	Impact of pneumococcal conjugate vaccine (PCV7 and PCV13) on pneumococcal invasive diseases in Italian children and insight into evolution of pneumococcal population structure. Vaccine, 2017, 35, 4587-4593.	1.7	43
141	Osteoarticular Infections Caused by Streptococcus pneumoniae in Children in the Postâ€“Pneumococcal Conjugate Vaccine Era. Pediatric Infectious Disease Journal, 2017, 36, 1201-1204.	1.1	26
142	The importance of immunization in cancer prevention, treatment, and survivorship. Ca-A Cancer Journal for Clinicians, 2017, 67, 398-410.	157.7	34
143	Pneumococcal Serotype 5 Colonization Prevalence Among Newly Arrived Unaccompanied Children 1 Year After an Outbreakâ€”Texas, 2015. Pediatric Infectious Disease Journal, 2017, 36, 236-238.	1.1	3
144	Cost-effectiveness of the 13-valent Pneumococcal Conjugate Vaccine in Children in Portugal. Pediatric Infectious Disease Journal, 2017, 36, 782-787.	1.1	5
145	Functional immune responses to 11 non-PCV13 serotypes after immunization with a 23-valent pneumococcal polysaccharide vaccine in older adults. Vaccine, 2017, 35, 4960-4965.	1.7	2
146	A Population-Based Assessment of the Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines on Macrolide-Resistant Invasive Pneumococcal Disease: Emergence and Decline of Streptococcus pneumoniae Serotype 19A (CC320) With Dual Macrolide Resistance Mechanisms. Clinical Infectious Diseases, 2017, 65, 990-998.	2.9	32
147	Comparison of the Impact of Pneumococcal Conjugate Vaccine 10 or Pneumococcal Conjugate Vaccine 13 on Invasive Pneumococcal Disease in Equivalent Populations. Clinical Infectious Diseases, 2017, 65, 1780-1790.e1.	2.9	123
148	Streptococcus pneumoniae serotype 19A: worldwide epidemiology. Expert Review of Vaccines, 2017, 16, 1007-1027.	2.0	98
150	Vaccine Science and Immunology. , 2017, , 41-70.		0

#	Article	IF	Citations
151	Safety and immunogenicity of a novel multiple antigen pneumococcal vaccine in adults: A Phase 1 randomised clinical trial. Vaccine, 2017, 35, 7181-7186.	1.7	33
152	Redistribution of Streptococcus pneumoniae Serotypes After Nationwide 13-valent Pneumococcal Conjugate Vaccine Program in Children in Northern Taiwan. Pediatric Infectious Disease Journal, 2017, 36, e334-e340.	1.1	14
153	Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy. Human Vaccines and Immunotherapeutics, 2017, 13, 2307-2315.	1.4	16
154	Surveillance of pneumococcal colonization and invasive pneumococcal disease reveals shift in prevalent carriage serotypes in Massachusettsâ€™ children to relatively low invasiveness. Vaccine, 2017, 35, 4002-4009.	1.7	41
155	Seasonality of stroke in Finland. Annals of Medicine, 2017, 49, 310-318.	1.5	34
156	Pneumococcal infections in elderly patients attending hospital since PCV-13 authorization in Spain. Infectious Diseases, 2017, 49, 71-80.	1.4	7
157	Long-term Impact of a â€œ3 + 0â€•Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002â€“2014. Clinical Infectious Diseases, 2017, 64, 175-183.	2.9	70
158	Multiplex Urinary Antigen Detection for 13 Streptococcus pneumoniae Serotypes Improves Diagnosis of Pneumococcal Pneumonia in South African HIV-Infected Adults. Journal of Clinical Microbiology, 2017, 55, 302-312.	1.8	8
159	Emergence of Multidrug-Resistant Pneumococcal Serotype 35B among Children in the United States. Journal of Clinical Microbiology, 2017, 55, 724-734.	1.8	74
160	Impact of a pharmacist-led pneumococcal vaccine compliance program. American Journal of Health-System Pharmacy, 2017, 74, 1948-1952.	0.5	5
162	Immunisation schedule of the Spanish Association of Paediatrics: 2017 recommendations. Vacunas (English Edition), 2017, 18, 71-78.	0.3	0
163	Characteristics and Serotype Distribution of Childhood Cases of Invasive Pneumococcal Disease Following Pneumococcal Conjugate Vaccination in England and Wales, 2006â€“2014. Clinical Infectious Diseases, 2017, 65, 1191-1198.	2.9	32
164	From the microbiome to the central nervous system, an update on the epidemiology and pathogenesis of bacterial meningitis in childhood. F1000Research, 2017, 6, 86.	0.8	7
165	Review Update on Pneumococcal Conjugate Vaccine: A New Hope for Reduction of Pneumococcal Disease in Bangladesh. Bangladesh Journal of Infectious Diseases, 2017, 2, 19-22.	0.1	0
166	Changes in the Serotype Distribution among Antibiotic Resistant CarriageStreptococcus pneumoniaeIsolates in Children after the Introduction of the Extended-Valency Pneumococcal Conjugate Vaccine. Journal of Korean Medical Science, 2017, 32, 1431.	1.1	16
167	Prevention of Community-Acquired Pneumonia with Available Pneumococcal Vaccines. International Journal of Molecular Sciences, 2017, 18, 30.	1.8	20
168	Pneumococcal Colonization in the Familial Context and Implications for Anti-Pneumococcal Immunization in Adults: Results from the BINOCOLO Project in Sicily. International Journal of Molecular Sciences, 2017, 18, 105.	1.8	10
169	Specialty Grand Challenge In Pediatric Infectious Diseases. Frontiers in Pediatrics, 2017, 5, 185.	0.9	4

#	Article	IF	Citations
170	Forecasting Trends in Invasive Pneumococcal Disease among Elderly Adults in Quebec. Canadian Journal of Infectious Diseases and Medical Microbiology, 2017, 2017, 1-7.	0.7	5
171	Invasive Pneumococcal Disease: Still Lots to Learn and a Need for Standardized Data Collection Instruments. Canadian Respiratory Journal, 2017, 2017, 1-9.	0.8	15
172	Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis. PLoS ONE, 2017, 12, e0169368.	1.1	166
173	Decrease of invasive pneumococcal disease (IPD) in adults after introduction of pneumococcal 13-valent conjugate vaccine in Spain. PLoS ONE, 2017, 12, e0175224.	1.1	47
174	Estimated severe pneumococcal disease cases and deaths before and after pneumococcal conjugate vaccine introduction in children younger than 5 years of age in South Africa. PLoS ONE, 2017, 12, e0179905.	1.1	37
175	Impact of vaccine herd-protection effects in cost-effectiveness analyses of childhood vaccinations. A quantitative comparative analysis. PLoS ONE, 2017, 12, e0172414.	1.1	9
176	Antibiotic prescriptions for outpatient acute rhinosinusitis in Canada, 2007-2013. PLoS ONE, 2017, 12, e0181957.	1.1	14
177	Determining the contribution of Streptococcus pneumoniae to communityâ€acquired pneumonia in Australia. Medical Journal of Australia, 2017, 207, 396-400.	0.8	13
178	Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia. Cost Effectiveness and Resource Allocation, 2017, 15, 17.	0.6	12
179	Evaluation of inpatient pneumococcal vaccination rate among adult patients with diabetes in a tertiary care teaching hospital in Saudi Arabia. International Diabetes Nursing, 2017, 14, 105-109.	0.1	0
180	The nasopharyngeal microbiome. Emerging Topics in Life Sciences, 2017, 1, 297-312.	1.1	14
181	Concurrent Infection with Hepatitis C Virus andStreptococcus pneumoniae. Emerging Infectious Diseases, 2017, 23, 1118-1123.	2.0	20
182	Increased Invasive Pneumococcal Disease, North East England, UK. Emerging Infectious Diseases, 2017, 23, 122-126.	2.0	25
183	Invasive Serotype 35B Pneumococci Including an Expanding Serotype Switch Lineage, United States, 2015â€“2016. Emerging Infectious Diseases, 2017, 23, 922-930.	2.0	52
185	Protecting the Community Through Child Vaccination. Clinical Infectious Diseases, 2018, 67, 464-471.	2.9	38
186	Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines in a Schedule Without a Booster Dose: A 10-Year Observational Study. Clinical Infectious Diseases, 2018, 67, 367-374.	2.9	35
187	Etiology of Acute Otitis Media and Characterization of Pneumococcal Isolates After Introduction of 13-Valent Pneumococcal Conjugate Vaccine in Japanese Children. Pediatric Infectious Disease Journal, 2018, 37, 598-604.	1.1	40
188	Modeling Possible Inclusion of Pneumococcal Conjugate Vaccine into the National Immunization Program for Infants in India. Value in Health Regional Issues, 2018, 15, 99-105.	0.5	5

#	Article	IF	Citations
189	Antimicrobial susceptibility and fluctuations in clonal complexes of serogroup 6 Streptococcus pneumoniae isolates collected from children in Beijing, China, between 1997 and 2016. Brazilian Journal of Microbiology, 2018, 49, 891-899.	0.8	2
190	Deconstructing Pneumococcal Progression from Colonization to Disease. Infection and Immunity, 2018, 86, .	1.0	1
191	A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand. Applied Health Economics and Health Policy, 2018, 16, 331-345.	1.0	6
192	Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review. Respiratory Medicine, 2018, 137, 6-13.	1.3	90
193	Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000â€“17: a prospective national observational cohort study. Lancet Infectious Diseases, The, 2018, 18, 441-451.	4.6	403
194	Use of data to drive pneumococcal conjugate vaccine policy. Lancet Infectious Diseases, The, 2018, 18, 366-368.	4.6	4
195	Prevention of Invasive Pneumococcal Disease: Problems Emerged After Some Years of the 13-Valent Pneumococcal Conjugate Vaccine Use. Current Infectious Disease Reports, 2018, 20, 1.	1.3	29
196	Pneumococcal Community-Acquired Pneumonia Detected by Serotype-Specific Urinary Antigen Detection Assays. Clinical Infectious Diseases, 2018, 66, 1504-1510.	2.9	46
197	Streptococcus pneumoniae. , 2018, , 737-746.e4.		2
198	Evaluation of Protective Efficacy of Selected Immunodominant B-Cell Epitopes within Virulent Surface Proteins of Streptococcus pneumoniae. Infection and Immunity, 2018, 86, .	1.0	9
199	Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74â€¯years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine, 2018, 36, 606-614.	1.7	14
200	Paediatric invasive pneumococcal disease on the island of Gran Canaria: 16-year prospective study (2001â€“2016). Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2018, 36, 607-611.	0.3	3
201	Early impact of 13-valent pneumococcal conjugate vaccine on pneumococcal meningitisâ€”Burkina Faso, 2014â€“2015. Journal of Infection, 2018, 76, 270-279.	1.7	27
202	Invasive pneumococcal disease in children under 16â€¯years of age: Incomplete rebound in incidence after the maximum effect of PCV13 in 2012/13 in Germany. Vaccine, 2018, 36, 572-577.	1.7	46
203	Quantifying the impact of mass vaccination programmes on notified cases in the Netherlands. Epidemiology and Infection, 2018, 146, 716-722.	1.0	14
204	Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naÃ¯ve adults â‰¥50 years of age. Vaccine, 2018, 36, 6875-6882.	1.7	35
205	Complicated pneumonia: current concepts and state of the art. Current Opinion in Pediatrics, 2018, 30, 384-392.	1.0	18
206	Comparative incidence dynamics and serotypes of meningitis, bacteremic pneumonia and other-IPD in young children in the PCV era: Insights from Israeli surveillance studies. Vaccine, 2018, 36, 5477-5484.	1.7	38

#	Article	IF	Citations
207	Clinical and microbiological characteristics of unusual manifestations of invasive pneumococcal disease. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2018, 36, 284-289.	0.3	10
208	Infections Associated With Group Childcare. , 2018, , 25-32.e3.		10
209	Active Immunization. , 2018, , 43-71.e4.		4
210	Acute Pneumonia and Its Complications. , 2018, , 238-249.e4.		9
211	Review of vaccine effectiveness assumptions used in economic evaluations of infant pneumococcal conjugate vaccine. Expert Review of Vaccines, 2018, 17, 71-78.	2.0	21
212	Bacterial microbiota of the nasal passages across the span of human life. Current Opinion in Microbiology, 2018, 41, 8-14.	2.3	80
213	Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1â€ˆ+â€ˆ1) compared with two primary doses and a booster (2â€ˆ+â€ˆ1) in UK infants: a multicentre, parallel group randomised controlled trial. Lancet Infectious Diseases, The, 2018, 18, 171-179.	4.6	97
214	Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec. Vaccine, 2018, 36, 421-426.	1.7	27
215	Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution. Expert Review of Vaccines, 2018, 17, 479-493.	2.0	73
216	Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea. Human Vaccines and Immunotherapeutics, 2018, 14, 85-94.	1.4	10
217	Trends in Invasive Pneumococcal Disease in Cancer Patients After the Introduction of 7-valent Pneumococcal Conjugate Vaccine: A 20-year Longitudinal Study at a Major Urban Cancer Center. Clinical Infectious Diseases, 2018, 66, 244-253.	2.9	11
218	Trends in Otitis Media and Myringotomy With Tube Placement Among American Indian and Alaska Native Children and the US General Population of Children After Introduction of the 13-valent Pneumococcal Conjugate Vaccine. Pediatric Infectious Disease Journal, 2018, 37, e6-e12.	1.1	14
219	Effect of Age on the Manifestations and Outcomes of Invasive Pneumococcal Disease in Adults. American Journal of Medicine, 2018, 131, 100.e1-100.e7.	0.6	35
220	Epidemiology, pathophysiology, and microbiology of community-acquired pneumonia. Annals of Research Hospitals, 0, 2, 1-1.	0.0	25
221	Licensure, Approval, and Uptake of Vaccines in the United States. Journal of the Pediatric Infectious Diseases Society, 2018, 7, S46-S48.	0.6	1
222	Paediatric invasive pneumococcal disease on the island of Gran Canaria: 16-year prospective study (2001â€“2016). Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2018, 36, 607-611.	0.2	0
223	Antimicrobial Resistance Among Streptococcus pneumoniae. , 2018, , 13-38.		20
224	Global emergence and population dynamics of divergent serotype 3 CC180 pneumococci. PLoS Pathogens, 2018, 14, e1007438.	2.1	74

#	Article	IF	Citations
225	Age-related changes in the levels and kinetics of pulmonary cytokine and chemokine responses to Streptococcuspneumoniae in mouse pneumonia models. Cytokine, 2018, 111, 389-397.	1.4	15
226	Vaccines to Prevent Pneumococcal Community-Acquired Pneumonia. Clinics in Chest Medicine, 2018, 39, 733-752.	0.8	21
227	Changes in the serotype distribution of Streptococcus pneumoniae causing otitis media after PCV13 introduction in Spain. PLoS ONE, 2018, 13, e0209048.	1.1	22
228	The Evolving Epidemiology of Serotype Distribution and Antimicrobial Resistance of Streptococcus pneumoniae Strains Isolated from Adults in Crete, Greece, 2009â€“2016. Infection and Chemotherapy, 2018, 50, 328.	1.0	9
229	Streptococcus mitis Expressing Pneumococcal Serotype 1 Capsule. Scientific Reports, 2018, 8, 17959.	1.6	37
230	Why the evolution of vaccine resistance is less of a concern than the evolution of drug resistance. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 12878-12886.	3.3	79
231	Ficolin-2 binds to serotype 35B pneumococcus as it does to serotypes 11A and 31, and these serotypes cause more infections in older adults than in children. PLoS ONE, 2018, 13, e0209657.	1.1	9
232	Effect of Vaccination on Pneumococci Isolated from the Nasopharynx of Healthy Children and the Middle Ear of Children with Otitis Media in Iceland. Journal of Clinical Microbiology, 2018, 56, .	1.8	26
233	Impact of existing vaccines in reducing antibiotic resistance: Primary and secondary effects. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 12896-12901.	3.3	141
234	A Population-Based Descriptive Atlas of Invasive Pneumococcal Strains Recovered Within the U.S. During 2015â€“2016. Frontiers in Microbiology, 2018, 9, 2670.	1.5	39
235	Expansion of the multidrug-resistant clonal complex 320 among invasive Streptococcus pneumoniae serotype 19A after the introduction of a ten-valent pneumococcal conjugate vaccine in Brazil. PLoS ONE, 2018, 13, e0208211.	1.1	49
236	Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. Vaccine, 2018, 36, 6883-6891.	1.7	79
237	The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage. Vaccine, 2018, 36, 7744-7752.	1.7	36
238	Conjugate vaccine serotypes persist as major causes of non-invasive pneumococcal pneumonia in Portugal despite declines in serotypes 3 and 19A (2012-2015). PLoS ONE, 2018, 13, e0206912.	1.1	12
239	Effects of Pneumococcal Conjugate Vaccine on Genotypic Penicillin Resistance and Serotype Changes, Japan, 2010â€“2017. Emerging Infectious Diseases, 2018, 24, 2010-2020.	2.0	98
240	The choice of analytical methodology can alter conclusions regarding herd effects of paediatric pneumococcal vaccination programmes. Vaccine, 2018, 36, 6933-6943.	1.7	2
241	Clinical and economic burden of pneumococcal disease in US adults aged 19â€“64Âyears with chronic or immunocompromising diseases: an observational database study. BMC Infectious Diseases, 2018, 18, 436.	1.3	44
242	14 Cerebral Infectious Processes. , 2018, , .		0

#	Article	IF	Citations
243	Pediatric Complicated Pneumonia Caused by Streptococcus pneumoniae Serotype 3 in 13-Valent Pneumococcal Conjugate Vaccinees, Portugal, 2010â€“2015. Emerging Infectious Diseases, 2018, 24, 1307-1314.	2.0	57
244	Effect of the introduction of pneumococcal conjugate vaccines on serotype prevalence in Kuwait and Saudi Arabia. Vaccine, 2018, 36, 6442-6448.	1.7	7
245	Antibiotic use for community-acquired pneumonia in neonates and children: WHO evidence review. Paediatrics and International Child Health, 2018, 38, S66-S75.	0.3	72
246	Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design. Clinical Infectious Diseases, 2018, 67, 1498-1506.	2.9	98
247	Invasive pneumococcal disease in Northern Alberta, not a Red Queen but a dark horse. Vaccine, 2018, 36, 2985-2990.	1.7	5
248	Serotype distribution of invasive Streptococcus pneumoniae in adults 65â€¯years of age and over after the introduction of childhood 13-valent pneumococcal conjugate vaccination programs in Canada, 2010â€“2016. Vaccine, 2018, 36, 4701-4707.	1.7	23
249	Pneumococcal Conjugate Vaccine and Pneumococcal Common Protein Vaccines. , 2018, , 773-815.e18.		9
250	Pneumococcal Polysaccharide Vaccines. , 2018, , 816-840.e13.		8
251	Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada. Infectious Diseases and Therapy, 2018, 7, 353-371.	1.8	29
252	Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China. PLoS ONE, 2018, 13, e0201245.	1.1	18
253	Incidence of paediatric pneumococcal meningitis and emergence of new serotypes: a time-series analysis of a 16-year French national survey. Lancet Infectious Diseases, The, 2018, 18, 983-991.	4.6	69
254	Opioid Analgesic Use and Risk for Invasive Pneumococcal Diseases. Annals of Internal Medicine, 2018, 168, 396.	2.0	75
255	Streptococcus pneumoniae serotype 19A in Latin America and the Caribbean 2010â€“2015: A systematic review and a time series analysis. Vaccine, 2018, 36, 4861-4874.	1.7	15
256	Testing for Respiratory Viruses in Adults With Severe Lower Respiratory Infection. Chest, 2018, 154, 1213-1222.	0.4	25
257	PCV13 vaccination impact: A multicenter study of pneumonia in 10 pediatric hospitals in Argentina. PLoS ONE, 2018, 13, e0199989.	1.1	11
258	Severe Austrian Syndrome in an Immunocompromised Adult Patient â€“ A Case Report. The Journal of Critical Care Medicine, 2018, 4, 17-22.	0.3	6
259	Cost-effectiveness of increasing vaccination in high-risk adults aged 18â€“64ÂYears: a model-based decision analysis. BMC Infectious Diseases, 2018, 18, 52.	1.3	14
260	Occult bacteremia etiology following the introduction of 13-valent pneumococcal conjugate vaccine: a multicenter study in Spain. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 1449-1455.	1.3	5

#	Article	IF	Citations
261	Pneumococcal Meningitis in Adults after Introduction of PCV7 and PCV13, Israel, July 2009â€“June 20151. Emerging Infectious Diseases, 2018, 24, 1275-1284.	2.0	18
262	Adherence to pneumococcal conjugate vaccination schedule and uptake rate as compared to the established diphtheria-tetanus-acellular pertussis vaccination in Cyprus. Vaccine, 2018, 36, 5685-5691.	1.7	6
263	The neuropathology of the adult cerebellum. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 154, 129-149.	1.0	48
264	Clinical and microbiological characteristics of unusual manifestations of invasive pneumococcal disease. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2018, 36, 284-289.	0.2	0
265	Development, Interlaboratory Evaluations, and Application of a Simple, High-Throughput Shigella Serum Bactericidal Assay. MSphere, 2018, 3, .	1.3	31
266	Invasive pneumococcal disease in Indian adults: 11 years' experience. Journal of Microbiology, Immunology and Infection, 2019, 52, 736-742.	1.5	27
268	Optimal approaches to preventing severe community-acquired pneumonia. Expert Review of Respiratory Medicine, 2019, 13, 1005-1018.	1.0	4
269	The changing epidemiology of communityâ€acquired pneumonia: nationwide registerâ€based study in Sweden. Journal of Internal Medicine, 2019, 286, 689-701.	2.7	26
270	Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN). Vaccine, 2019, 37, 5466-5473.	1.7	29
271	Manual of Travel Medicine. , 2019, , .		3
272	Kawasaki Disease following administration of 13-valent pneumococcal conjugate vaccine in young children. Scientific Reports, 2019, 9, 14705.	1.6	14
273	Impact of 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis, Burkina Faso, 2016â€“2017. Journal of Infectious Diseases, 2019, 220, S253-S262.	1.9	21
274	Limited indirect effects of an infant pneumococcal vaccination program in an aging population. PLoS ONE, 2019, 14, e0220453.	1.1	63
275	Streptococcus pneumoniae Acquisition and Carriage. Indian Journal of Pediatrics, 2019, 86, 979-980.	0.3	1
276	Prevalence of Immunodeficiency in Children With Invasive Pneumococcal Disease in the Pneumococcal Vaccine Era. JAMA Pediatrics, 2019, 173, 1084.	3.3	25
277	Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Severe Invasive Disease Caused by Serotype 3 Streptococcus Pneumoniae in Italian Children. Vaccines, 2019, 7, 128.	2.1	7
278	Invasive Pneumococcal Disease in Childrenâ€™s Hospitals: 2014â€“2017. Pediatrics, 2019, 144, .	1.0	32
279	Genome-wide association analyses of invasive pneumococcal isolates identify a missense bacterial mutation associated with meningitis. Nature Communications, 2019, 10, 178.	5.8	33

#	Article	IF	Citations
280	Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults. Human Vaccines and Immunotherapeutics, 2019, 15, 530-539.	1.4	80
281	Streptococcus pneumoniae colonization after introduction of 13-valent pneumococcal conjugate vaccine for US adults 65 years of age and older, 2015â€“2016. Vaccine, 2019, 37, 1094-1100.	1.7	23
282	Making sense of differences in pneumococcal serotype replacement. Lancet Infectious Diseases, The, 2019, 19, e213-e220.	4.6	100
283	A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. Human Vaccines and Immunotherapeutics, 2019, 15, 549-559.	1.4	55
284	Acute otitis media in infants younger than two months of age: Epidemiologic and microbiologic characteristics in the era of pneumococcal conjugate vaccines. International Journal of Pediatric Otorhinolaryngology, 2019, 119, 123-130.	0.4	6
285	Semisynthetic Glycoconjugate Vaccines To Elicit T Cell-Mediated Immune Responses and Protection against Streptococcus pneumoniae Serotype 3. ACS Infectious Diseases, 2019, 5, 1423-1432.	1.8	13
286	Evolution of serotypes in bacteremic pneumococcal adult pneumonia in the period 2001â€“2014, after introduction of the pneumococcal conjugate vaccine in bizkaia (spain). Vaccine, 2019, 37, 3840-3848.	1.7	5
287	The complexity of serotype replacement of pneumococci. Human Vaccines and Immunotherapeutics, 2019, 15, 2725-2728.	1.4	8
288	Relationship between immune response to pneumococcal conjugate vaccines in infants and indirect protection after vaccine implementation. Expert Review of Vaccines, 2019, 18, 641-661.	2.0	26
289	A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands. Vaccine, 2019, 37, 4147-4154.	1.7	30
290	Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study. Lancet Infectious Diseases, The, 2019, 19, 759-769.	4.6	165
291	12 years active surveillance for pediatric pleural empyema in a Mexican hospital: effectiveness of pneumococcal 13-valent conjugate vaccine, and early emergence of methicillin-resistant Staphylococcus aureus. Therapeutic Advances in Infectious Disease, 2019, 6, 204993611983931.	1.1	10
292	Effects of Pneumococcal Conjugate Vaccine in the United Kingdom: Success of Vaccine Policy and Remaining Opportunities for Prevention. Journal of Infectious Diseases, 2019, 221, 1235-1237.	1.9	1
293	Population versus individual protection by pneumococcal conjugate vaccination. Lancet, The, 2019, 393, 2102-2104.	6.3	7
294	Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study. Lancet, The, 2019, 393, 2146-2154.	6.3	111
295	Timing Is Everything: Pneumococcal Immunization in Inflammatory Bowel Disease. Clinical Infectious Diseases, 2020, 70, 605-607.	2.9	0
296	Emerging Challenges and Opportunities in Infectious Disease Epidemiology. American Journal of Epidemiology, 2019, 188, 873-882.	1.6	14
297	Antimicrobial Susceptibility of Streptococcus pneumoniae from North America, Europe, Latin America, and the Asia-Pacific Region: Results From 20 Years of the SENTRY Antimicrobial Surveillance Program (1997â€“2016). Open Forum Infectious Diseases, 2019, 6, S14-S23.	0.4	56

#	Article	IF	Citations
298	Genomic Analyses of >3,100 Nasopharyngeal Pneumococci Revealed Significant Differences Between Pneumococci Recovered in Four Different Geographical Regions. Frontiers in Microbiology, 2019, 10, 317.	1.5	9
299	Cost-effectiveness of adult pneumococcal vaccination policies in underserved minorities aged 50â€“64â€¯years compared to the US general population. Vaccine, 2019, 37, 2026-2033.	1.7	12
300	Changes in Invasive Pneumococcal Disease Spectrum After 13-Valent Pneumococcal Conjugate Vaccine Implementation. Clinical Infectious Diseases, 2020, 70, 446-454.	2.9	24
301	Impact of the pediatric 13-valent pneumococcal conjugate vaccine on serotype distribution and clinical characteristics of pneumococcal pneumonia in adults: The Japan Pneumococcal Vaccine Effectiveness Study (J-PAVE). Vaccine, 2019, 37, 2687-2693.	1.7	27
302	Successful Control of Streptococcus pneumoniae 19A Replacement With a Catch-up Primary Vaccination Program in Taiwan. Clinical Infectious Diseases, 2019, 69, 1581-1587.	2.9	39
303	Herd protection or herding cats?. Thorax, 2019, 74, 425-426.	2.7	1
304	Preventive effects of pneumococcal and influenza vaccines on community-acquired pneumonia in older individuals in Japan: a case-control study. Human Vaccines and Immunotherapeutics, 2019, 15, 2171-2177.	1.4	11
305	Cost-Effectiveness Comparison of Pneumococcal Conjugate Vaccines in Turkish Children. Value in Health Regional Issues, 2019, 19, 34-44.	0.5	7
306	Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States. Expert Review of Vaccines, 2019, 18, 327-341.	2.0	35
307	Invasive Pneumococcal and Meningococcal Disease. Infectious Disease Clinics of North America, 2019, 33, 1125-1141.	1.9	25
308	The shifting epidemiology and serotype distribution of invasive pneumococcal disease in Ontario, Canada, 2007-2017. PLoS ONE, 2019, 14, e0226353.	1.1	47
309	Serotype Distribution, Antimicrobial Susceptibility, and Multilocus Sequencing Type (MLST) of Streptococcus pneumoniae From Adults of Three Hospitals in Shanghai, China. Frontiers in Cellular and Infection Microbiology, 2019, 9, 407.	1.8	14
310	Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico. Human Vaccines and Immunotherapeutics, 2019, 15, 560-569.	1.4	19
311	Persistence of Nasopharyngeal Pneumococcal Vaccine Serotypes and Increase of Nonvaccine Serotypes Among Vaccinated Infants and Their Mothers 5 Years After Introduction of Pneumococcal Conjugate Vaccine 13 in The Gambia. Clinical Infectious Diseases, 2019, 68, 1512-1521.	2.9	41
312	Burden of Streptococcus pneumoniae Sepsis in Children After Introduction of Pneumococcal Conjugate Vaccines: A Prospective Population-based Cohort Study. Clinical Infectious Diseases, 2019, 69, 1574-1580.	2.9	18
314	Effects of Anaerobic Culturing on Pathogenicity and Virulence-Related Gene Expression in Pneumococcal Pneumonia. Journal of Infectious Diseases, 2019, 219, 1545-1553.	1.9	6
315	Streptococcus pneumoniae Serotype 3 in Mexico (1994 to 2017): Decrease of the Unusual Clonal Complex 4909 Lineage following PCV13 Introduction. Journal of Clinical Microbiology, 2019, 57, .	1.8	8
316	Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination. Thorax, 2019, 74, 473-482.	2.7	125

#	Article	IF	Citations
317	Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults â‰¥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Human Vaccines and Immunotherapeutics, 2019, 15, 540-548.	1.4	35
318	Should Pneumococcal Serotype 3 Be Included in Serotype-Specific Immunoassays?. Vaccines, 2019, 7, 4.	2.1	33
319	Indirect effect of 7-valent and 13-valent pneumococcal conjugated vaccines on pneumococcal pneumonia hospitalizations in elderly. PLoS ONE, 2019, 14, e0209428.	1.1	9
320	Pneumococcal Vaccines in Adults. , 2019, , 201-212.		0
321	An intervention to improve pneumococcal vaccination uptake in high risk 50-64 year olds vs. expanded age-based recommendations: an exploratory cost-effectiveness analysis. Human Vaccines and Immunotherapeutics, 2019, 15, 863-872.	1.4	9
322	Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program. PLoS ONE, 2019, 14, e0210081.	1.1	25
323	Regional variations in serotype distribution and vaccination status in children under six years of age with invasive pneumococcal disease in Germany. PLoS ONE, 2019, 14, e0210278.	1.1	10
324	Limited impact of pneumococcal vaccines on invasive pneumococcal disease in Nunavik (Quebec). Canadian Journal of Public Health, 2019, 110, 36-43.	1.1	5
325	Impact of the 13-Valent Pneumococcal Conjugate Vaccine Among Adults: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2019, 69, 34-49.	2.9	44
326	Cost-Effectiveness of the Pneumococcal Conjugate Vaccine (10- or 13-Valent) Versus No Vaccination for a National Immunization Program in Tunisia or Algeria. Infectious Diseases and Therapy, 2019, 8, 63-74.	1.8	11
327	Serotype distribution, antibiotic resistance pattern, and multilocus sequence types of invasive Streptococcus pneumoniae isolates in two tertiary pediatric hospitals in Beijing prior to PCV13 availability. Expert Review of Vaccines, 2019, 18, 89-94.	2.0	16
328	Decline in Pneumococcal Disease Attenuated in Older Adults and Those With Comorbidities Following Universal Childhood PCV13 Immunization. Clinical Infectious Diseases, 2019, 68, 1831-1838.	2.9	28
329	Disproportionate Exposure to Antibiotics in Children at Risk for Invasive Pneumococcal Disease: Potential for Emerging Resistance and Opportunity for Antibiotic Stewardship. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 63-65.	0.6	5
330	Bacterial Infections of the CentralÂNervous System. Indian Journal of Pediatrics, 2019, 86, 60-69.	0.3	36
331	Assessing the Impact of Pneumococcal Conjugate Vaccines. Clinical Infectious Diseases, 2020, 70, 1589-1590.	2.9	5
332	Early Signals of Vaccine-driven Perturbation Seen in Pneumococcal Carriage Population Genomic Data. Clinical Infectious Diseases, 2020, 70, 1294-1303.	2.9	9
333	Multistate population and whole genome sequence-based strain surveillance of invasive pneumococci recovered in the USA during 2017. Clinical Microbiology and Infection, 2020, 26, 512.e1-512.e10.	2.8	37
334	Changes in serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates from adult patients in Asia: Emergence of drug-resistant non-vaccine serotypes. Vaccine, 2020, 38, 6065-6073.	1.7	57

#	Article	IF	Citations
335	Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013â€“18. Thorax, 2020, 75, 38-49.	2.7	75
336	Long-term Impact of Pneumococcal Conjugate Vaccines on Invasive Disease and Pneumonia Hospitalizations in Indigenous and Non-Indigenous Australians. Clinical Infectious Diseases, 2020, 70, 2607-2615.	2.9	16
337	Resurgence of pneumococcal meningitis in Europe and Northern America. Clinical Microbiology and Infection, 2020, 26, 199-204.	2.8	53
338	Early Impact of 13-Valent Pneumococcal Conjugate Vaccine Use on Invasive Pneumococcal Disease Among Adults With and Without Underlying Medical Conditionsâ€”United States. Clinical Infectious Diseases, 2020, 70, 2484-2492.	2.9	49
339	Invasive Streptococcus pneumoniae Infections and Vaccine Failures in Children in Ireland From the Postvaccine Era From 2007 to 2018. Pediatric Infectious Disease Journal, 2020, 39, 339-344.	1.1	11
340	Respiratory pathogens â€“ Some altered antibiotic susceptibility after implementation of pneumococcus vaccine and antibiotic control strategies. Journal of Microbiology, Immunology and Infection, 2020, 53, 682-689.	1.5	9
341	Routine Childhood Vaccines Given in the First 11 Months of Life. Mayo Clinic Proceedings, 2020, 95, 395-405.	1.4	5
342	Increase in Streptococcus pneumoniae serotype 3 associated parapneumonic pleural effusion/empyema after the introduction of PCV13 in Germany. Vaccine, 2020, 38, 570-577.	1.7	37
343	Routine infant vaccination of pneumococcal conjugate vaccines has decreased pneumonia across all age groups in Northern Spain. Human Vaccines and Immunotherapeutics, 2020, 16, 1446-1453.	1.4	5
344	Immunogenicity Comparison of a Next Generation Pneumococcal Conjugate Vaccine in Animal Models and Human Infants. Pediatric Infectious Disease Journal, 2020, 39, 70-77.	1.1	10
345	Dose-specific Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines Against Vaccine-serotype Streptococcus pneumoniae Colonization in Children. Clinical Infectious Diseases, 2020, 71, e289-e300.	2.9	22
346	Paediatric pneumonia in high-income countries: Defining and recognising cases at increased risk of severe disease. Paediatric Respiratory Reviews, 2020, 39, 71-81.	1.2	1
347	Incidence of invasive pneumococcal disease after introduction of the 13-valent conjugate pneumococcal vaccine in British Columbia: A retrospective cohort study. PLoS ONE, 2020, 15, e0239848.	1.1	8
348	Ten year public health impact of 13-valent pneumococcal conjugate vaccination in infants: A modelling analysis. Vaccine, 2020, 38, 7138-7145.	1.7	23
349	Impact of pneumococcal conjugate vaccine on pneumonia hospitalization and mortality in children and elderly in Ecuador: Time series analyses. Vaccine, 2020, 38, 7033-7039.	1.7	10
350	Warp Speed for Coronavirus Disease 2019 (COVID-19) Vaccines: Why Are Children Stuck in Neutral?. Clinical Infectious Diseases, 2021, 73, 336-340.	2.9	70
351	Nationwide Trends of Invasive Pneumococcal Disease in Spain From 2009 Through 2019 in Children and Adults During the Pneumococcal Conjugate Vaccine Era. Clinical Infectious Diseases, 2021, 73, e3778-e3787.	2.9	70
352	A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants. Pediatric Infectious Disease Journal, 2020, 39, 763-770.	1.1	41

#	Article	IF	Citations
353	Invasive Pneumococcal Strain Distributions and Isolate Clusters Associated With Persons Experiencing Homelessness During 2018. Clinical Infectious Diseases, 2021, 72, e948-e956.	2.9	14
354	Diagnosis and management of community-acquired pneumonia in children: South African Thoracic Society guidelines. African Journal of Thoracic and Critical Care Medicine, 2020, 26, 98.	0.3	14
355	Impact of the 13-Valent Conjugated Pneumococcal Vaccine on the Direct Costs of Invasive Pneumococcal Disease Requiring Hospital Admission in Children Aged < 5 Years: A Prospective Study. Vaccines, 2020, 8, 387.	2.1	0
356	Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age. Clinical Infectious Diseases, 2021, 73, e1489-e1497.	2.9	98
357	Pediatric parapneumonic effusion before and after national pneumococcal vaccination programs in Taiwan. Journal of the Formosan Medical Association, 2020, 119, 1608-1618.	0.8	8
358	Serotype distribution of Streptococcus pneumoniae isolated from children hospitalized in Beijing childrenâ€™s hospital (2013â€“2019). Vaccine, 2020, 38, 7858-7864.	1.7	13
359	Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in children in the United States. Journal of Medical Economics, 2020, 23, 1653-1660.	1.0	8
360	Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine for children in Taiwan. Cost Effectiveness and Resource Allocation, 2020, 18, 30.	0.6	6
361	Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013â€“2017. Emerging Infectious Diseases, 2020, 26, 2378-2386.	2.0	16
362	The Impact of Rapid Species Identification on Management of Bloodstream Infections. Mayo Clinic Proceedings, 2020, 95, 2509-2524.	1.4	5
363	Co-seasonality and co-detection of respiratory viruses and bacteraemia in children: a retrospective analysis. Clinical Microbiology and Infection, 2020, 26, 1690.e5-1690.e8.	2.8	10
364	Population impact and effectiveness of sequential 13-valent pneumococcal conjugate and monovalent rotavirus vaccine introduction on infant mortality: prospective birth cohort studies from Malawi. BMJ Global Health, 2020, 5, e002669.	2.0	5
365	Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valency. Scientific Reports, 2020, 10, 18977.	1.6	76
366	Comparison of anti-capsular antibody quantity and functionality in children after different primary dose and booster schedules of 13 valent-pneumococcal conjugate vaccine. Vaccine, 2020, 38, 4423-4431.	1.7	6
367	High residual carriage of vaccine-serotype Streptococcus pneumoniae after introduction of pneumococcal conjugate vaccine in Malawi. Nature Communications, 2020, 11, 2222.	5.8	79
368	High prevalence of antimicrobial resistance in non-vaccine serotypes of non-invasive/colonization isolates of Streptococcus pneumoniae: A cross-sectional study eight years after the licensure of conjugate vaccine in Japan. Journal of Infection and Public Health, 2020, 13, 1094-1100.	1.9	17
369	Increasing non-susceptibility to antibiotics within carried pneumococcal serotypes â€” Alaska, 2008â€“2015. Vaccine, 2020, 38, 4273-4280.	1.7	1
370	Vaccines Against Antimicrobial Resistance. Frontiers in Immunology, 2020, 11, 1048.	2.2	76

#	Article	IF	Citations
371	Development of Next Generation Streptococcus pneumoniae Vaccines Conferring Broad Protection. Vaccines, 2020, 8, 132.	2.1	90
372	Multicenter Hospital-Based Prospective Surveillance Study of Bacterial Agents Causing Meningitis and Seroprevalence of Different Serogroups of Neisseria meningitidis, Haemophilus influenzae Type b, and Streptococcus pneumoniae during 2015 to 2018 in Turkey. MSphere, 2020, 5, .	1.3	21
373	Clinical Relevance and Molecular Pathogenesis of the Emerging Serotypes 22F and 33F of Streptococcus pneumoniae in Spain. Frontiers in Microbiology, 2020, 11, 309.	1.5	27
374	Vaccination with conjugate vaccines against pneumococcal disease: What really matters. Vacunas (English Edition), 2020, 21, 23-40.	0.3	0
375	Other Respiratory Viruses as a Cause of Community-Acquired Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 579-591.	0.8	2
376	Serotype and clonal distribution dynamics of invasive pneumococcal strains after PCV13 introduction (2011-2016): Surveillance data from 23 sites in Catalonia, Spain. PLoS ONE, 2020, 15, e0228612.	1.1	18
377	Impact of the 10-valent pneumococcal conjugate vaccine on hospital admissions in children under three years of age in Iceland. Vaccine, 2020, 38, 2707-2714.	1.7	7
378	Pneumococcal Conjugate Vaccine Breakthrough Infections: 2001â€“2016. Pediatrics, 2020, 145, .	1.0	22
379	Emergence of Streptococcus pneumoniae serotype 19A (Spn19A) in the pediatric population in BogotÃ¡, Colombia as the main cause of invasive pneumococcal disease after the introduction of PCV10. Human Vaccines and Immunotherapeutics, 2020, 16, 2300-2306.	1.4	18
380	Costâ€Effectiveness of Pneumococcal Vaccination Policies and Uptake Programs in US Older Populations. Journal of the American Geriatrics Society, 2020, 68, 1271-1278.	1.3	7
381	State-of-the-art in the pneumococcal field: Proceedings of the 11th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-11). Pneumonia (Nathan Qld), 2020, 12, 2.	2.5	15
382	Pneumococcal Vaccination in Adults Aged â‰¥65 Years: Cost-Effectiveness and Health Impact in U.S. Populations. American Journal of Preventive Medicine, 2020, 58, 487-495.	1.6	9
383	Hemophagocytic lymphohistiocytosis complicating invasive pneumococcal disease: a pediatric case report. BMC Pediatrics, 2020, 20, 15.	0.7	1
384	Estimating the population health and economic impacts of introducing a pneumococcal conjugate vaccine in Malaysia- an economic evaluation. Human Vaccines and Immunotherapeutics, 2020, 16, 1719-1727.	1.4	11
385	Evaluation of the effectiveness of pneumococcal conjugate vaccine for children in Korea with high vaccine coverage using a propensity score matched national population cohort. International Journal of Infectious Diseases, 2020, 93, 146-150.	1.5	11
386	Complication of otitis media leads to opisthotonos in a toddler. American Journal of Emergency Medicine, 2020, 38, 1296.e5-1296.e7.	0.7	1
387	The impact of childhood 13-valent pneumococcal conjugate vaccination on overall invasive pneumococcal disease, including the oldest old. Acta Clinica Belgica, 2020, 76, 1-8.	0.5	5
388	Vaccines to Protect Older Adults against Pneumococcal Disease. Interdisciplinary Topics in Gerontology and Geriatrics, 2020, 43, 113-130.	2.6	7

#	Article	IF	Citations
389	New live attenuated tuberculosis vaccine MTBVAC induces trained immunity and confers protection against experimental lethal pneumonia. PLoS Pathogens, 2020, 16, e1008404.	2.1	58
390	Marked Reduction of Socioeconomic and Racial Disparities in Invasive Pneumococcal Disease Associated With Conjugate Pneumococcal Vaccines. Journal of Infectious Diseases, 2021, 223, 1250-1259.	1.9	5
391	Invasive pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: an interrupted time-series analysis of data from a 17-year national prospective surveillance study. Lancet Infectious Diseases, The, 2021, 21, 137-147.	4.6	70
392	Time for a third-generation pneumococcal conjugate vaccine. Lancet Infectious Diseases, The, 2021, 21, 14-16.	4.6	20
393	Comparison of PCV-10 and PCV-13 vaccine coverage for invasive pneumococcal isolates obtained across Canadian geographic regions, SAVE 2011 to 2017. Diagnostic Microbiology and Infectious Disease, 2021, 99, 115282.	0.8	7
394	Drastic reduction in pneumococcal meningitis in children owing to the introduction of pneumococcal conjugate vaccines: Longitudinal analysis from 2002 to 2016 in Japan. Journal of Infection and Chemotherapy, 2021, 27, 604-612.	0.8	11
395	Direct effects of pneumococcal conjugate vaccines among children in Latin America and the Caribbean. Lancet Infectious Diseases, The, 2021, 21, 306-308.	4.6	3
396	Vaccines for multidrug resistant Gram negative bacteria: lessons from the past for guiding future success. FEMS Microbiology Reviews, 2021, 45, .	3.9	18
397	Impact of PCVâ€13 vaccine on invasive pneumococcal disease in hospitalised children: A multiâ€institutional analysis. Acta Paediatrica, International Journal of Paediatrics, 2021, 110, 624-630.	0.7	2
398	Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea. Human Vaccines and Immunotherapeutics, 2021, 17, 909-918.	1.4	10
399	Molecular epidemiological characterization in mucoid-type Streptococcus pneumoniae isolates obtained from invasive pneumococcal disease patients in Japan. Journal of Infection and Chemotherapy, 2021, 27, 211-217.	0.8	5
400	Summary of evidence to reduce the two-dose infant priming schedule to a single dose of the 13-valent pneumococcal conjugate vaccine in the national immunisation programme in the UK. Lancet Infectious Diseases, The, 2021, 21, e93-e102.	4.6	7
401	Experimental Model for Studies of Pneumococcal Colonization in Older Adults. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 539-540.	2.5	1
402	Upsurge of Conjugate Vaccine Serotype 4 Invasive Pneumococcal Disease Clusters Among Adults Experiencing Homelessness in California, Colorado, and New Mexico. Journal of Infectious Diseases, 2021, 223, 1241-1249.	1.9	17
403	Human Gut Microbiome: A Potential Prospective to Counter Antibiotic-Resistant Pathogens. , 2022, , 368-368.		2
404	Application of the screening and indirect cohort methods to evaluate the effectiveness of pneumococcal vaccination program in adults 75â€‰years and older in Taiwan. BMC Infectious Diseases, 2021, 21, 45.	1.3	6
405	Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naÃ¯ve and previously immunized adult patients with severe chronic kidney disease. Vaccine, 2021, 39, 699-710.	1.7	4
406	Impact of pneumococcal conjugate vaccine on invasive pneumococcal disease in children under 5 years of age in the Czech Republic. PLoS ONE, 2021, 16, e0247862.	1.1	2

#	Article	IF	Citations
407	Costs implications of pneumococcal vaccination of adults aged 30â€“60 with a recent diagnosis of diabetes. Vaccine, 2021, 39, 1333-1338.	1.7	2
408	Effect of childhood pneumococcal vaccination and beta-lactam antibiotic use on the incidence of invasive pneumococcal disease in the adult population. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 1529-1538.	1.3	2
409	A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States. Human Vaccines and Immunotherapeutics, 2021, 17, 2249-2256.	1.4	7
410	National database study of trends in bacteraemia aetiology among children and adults in Japan: a longitudinal observational study. BMJ Open, 2021, 11, e043774.	0.8	10
411	Comparison of specific in-vitro virulence gene expression and innate host response in locally invasive vs colonizer strains of Streptococcus pneumoniae. Medical Microbiology and Immunology, 2021, 210, 111-120.	2.6	1
412	Vaccines against antimicrobial resistance: a promising escape route for multidrug resistance. Pharmaceutical Patent Analyst, 2021, 10, 83-98.	0.4	2
413	Pneumococcal Competition Modulates Antibiotic Resistance in the Pre-Vaccination Era: A Modelling Study. Vaccines, 2021, 9, 265.	2.1	5
414	A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age. Human Vaccines and Immunotherapeutics, 2021, 17, 2691-2699.	1.4	2
415	Similar impact and replacement disease after pneumococcal conjugate vaccine introduction in hospitalised children with invasive pneumococcal disease in Europe and North America. Vaccine, 2021, 39, 1551-1555.	1.7	7
416	Effect of prophylactic administration of antipyretics on the immune response to pneumococcal conjugate vaccines in children: a systematic review. Pneumonia (Nathan Qld), 2021, 13, 7.	2.5	6
417	The Impact of Pneumococcal Conjugate Vaccine (PCV) Coverage Heterogeneities on the Changing Epidemiology of Invasive Pneumococcal Disease in Switzerland, 2005â€“2019. Microorganisms, 2021, 9, 1078.	1.6	7
418	Serotype distribution of invasive, non-invasive and carried Streptococcus pneumoniae in Malaysia: a meta-analysis. Pneumonia (Nathan Qld), 2021, 13, 9.	2.5	9
419	Non-clinical immunological comparison of a Next-Generation 24-valent pneumococcal conjugate vaccine (VAX-24) using site-specific carrier protein conjugation to the current standard of care (PCV13) Tj ETQq0 0 1 rgBT /Overlock 10	1.7	26
420	Epidemiology of Pediatric Meningitis in South Korea From 2010 to 2018: A Population-based Retrospective Cohort Study. Pediatric Infectious Disease Journal, 2021, 40, 885-891.	1.1	3
421	Seconeolitsine, the Novel Inhibitor of DNA Topoisomerase I, Protects against Invasive Pneumococcal Disease Caused by Fluoroquinolone-Resistant Strains. Antibiotics, 2021, 10, 573.	1.5	2
422	Cost-Effectiveness Analysis of 23-Valent Pneumococcal Polysaccharide Vaccine Program for the Elderly Aged 60 Years or Older in Shanghai, China. Frontiers in Public Health, 2021, 9, 647725.	1.3	2
423	Invasive pneumococcal disease in Canada 2010â€“2017: The role of current and next-generation higher-valent pneumococcal conjugate vaccines. Vaccine, 2021, 39, 3007-3017.	1.7	10
424	Long-term population effects of infant 10-valent pneumococcal conjugate vaccination on pneumococcal meningitis in Finland. Vaccine, 2021, 39, 3216-3224.	1.7	5

#	Article	IF	Citations
425	Expanded Analysis of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-acquired Pneumonia in Hospitalized US Adults. Clinical Infectious Diseases, 2021, 73, 1216-1222.	2.9	33
426	Streptococcus Pneumoniae-Associated Hemolytic Uremic Syndrome in the Era of Pneumococcal Vaccine. Pathogens, 2021, 10, 727.	1.2	10
427	Female Patient with Invasive Pneumococcal Disease Due to Non-vaccine Serotype 24B <i>Streptococcus pneumoniae</i>. An Official Journal of the Japan Primary Care Association, 2021, 44, 81-84.	0.1	0
428	Streptococcus pneumoniae serotype 3 genotypes in invasive isolates from Colombia. Biomedica, 2021, 41, 338-346.	0.3	2
429	Serotype-Switch Variant of Multidrug-Resistant Streptococcus pneumoniae Sequence Type 271. Emerging Infectious Diseases, 2021, 27, 1689-1692.	2.0	9
430	A pragmatic health centre-based evaluation comparing the effectiveness of a PCV13 schedule change from 3+0 to 2+1 in a high pneumococcal carriage and disease burden setting in Malawi: a study protocol. BMJ Open, 2021, 11, e050312.	0.8	2
431	Burden of pneumococcal disease among adults in Southern Europe (Spain, Portugal, Italy, and Greece): a systematic review and meta-analysis. Human Vaccines and Immunotherapeutics, 2021, 17, 3670-3686.	1.4	9
432	Chronic Disease and Immunosuppression Increase the Risk for Nonvaccine Serotype Pneumococcal Disease: A Nationwide Population-based Study. Clinical Infectious Diseases, 2022, 74, 1338-1349.	2.9	8
433	Clinical Epidemiology and Outcomes of Pediatric Musculoskeletal Infections. Journal of Pediatrics, 2021, 234, 236-244.e2.	0.9	19
434	Streptococcus pneumoniae. Pediatrics in Review, 2021, 42, 349-359.	0.2	3
435	Pediatric Invasive Pneumococcal Disease Three Years after PCV13 Introduction in the National Immunization Planâ€"The Continued Importance of Serotype 3. Microorganisms, 2021, 9, 1428.	1.6	7
436	Immunogenicity of PCV24, an expanded pneumococcal conjugate vaccine, in adult monkeys and protection in mice. Vaccine, 2021, 39, 4231-4237.	1.7	9
437	Using genomics to examine the persistence of Streptococcus pneumoniae serotype 19A in Ireland and the emergence of a sub-clade associated with vaccine failures. Vaccine, 2021, 39, 5064-5073.	1.7	9
438	Bacterial factors required for Streptococcus pneumoniae coinfection with influenza A virus. Journal of Biomedical Science, 2021, 28, 60.	2.6	5
439	Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States. Pediatric Infectious Disease Journal, 2021, 40, 944-951.	1.1	28
440	High Prevalence of Vaccine-Type Infections Among Children with Pneumococcal Pneumonia and Effusion After 13-Valent Pneumococcal Conjugate Vaccine Introduction in the Dominican Republic. Journal of Infectious Diseases, 2021, 224, S228-S236.	1.9	2
441	Estimating the risk of recurrent invasive pneumococcal disease in Australia, 1991â€"2016. Vaccine, 2021, 39, 5748-5756.	1.7	1
442	Impact of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease and pneumonia in The Gambia: 10 years of population-based surveillance. Lancet Infectious Diseases, The, 2021, 21, 1293-1302.	4.6	22

#	Article	IF	Citations
443	Ã‡ocuklarda Akut Bakteriyel Menenjitlere GÃ¼ncel YaklaÅŸÄ±m. Turkish Journal of Pediatric Disease, 0, , 1-10.	0.0	0
444	Pneumococcal Carriage in Burkina Faso After 13-Valent Pneumococcal Conjugate Vaccine Introduction: Results From 2 Cross-sectional Population-Based Surveys. Journal of Infectious Diseases, 2021, 224, S258-S266.	1.9	4
445	Public health impact of pneumococcal conjugate vaccination: a review of measurement challenges. Expert Review of Vaccines, 2021, 20, 1-19.	2.0	8
446	Emergence of serotype 10A-ST11189 among pediatric invasive pneumococcal diseases, South Korea, 2014â€“2019. Vaccine, 2021, 39, 5787-5793.	1.7	4
447	A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age. Vaccine, 2021, 39, 5428-5435.	1.7	36
448	A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE). Vaccine, 2022, 40, 162-172.	1.7	40
449	Invasive pneumococcal disease caused by serotypes 22F and 33F in Canada: the SAVE study 2011â€“2018. Diagnostic Microbiology and Infectious Disease, 2021, 101, 115447.	0.8	7
450	Constrained Optimization for Pneumococcal Vaccination in Brazil. Value in Health Regional Issues, 2021, 26, 40-49.	0.5	1
451	Streptococcus pneumoniae. , 2022, , 1-13.		0
452	Evaluating the effectiveness of the 4CMenB vaccine against invasive meningococcal disease and gonorrhoea in an infant, child and adolescent program: protocol. Human Vaccines and Immunotherapeutics, 2021, 17, 1450-1454.	1.4	8
453	Cost-effectiveness of implementing 13-valent pneumococcal conjugate vaccine for U.S. adults aged 19 years and older with underlying conditions. Human Vaccines and Immunotherapeutics, 2021, 17, 2232-2240.	1.4	1
454	Carriage Dynamics of Pneumococcal Serotypes in Naturally Colonized Infants in a Rural African Setting During the First Year of Life. Frontiers in Pediatrics, 2020, 8, 587730.	0.9	8
455	Synthetic Analogs of Streptococcus pneumoniae Capsular Polysaccharides and Immunogenic Activities of Glycoconjugates. Russian Journal of Bioorganic Chemistry, 2021, 47, 1-25.	0.3	11
456	Acute otitis media and pneumococcal vaccination â€“ an observational cross-sectional study of otitis media among vaccinated and unvaccinated children in Greenland. International Journal of Circumpolar Health, 2021, 80, 1858615.	0.5	5
457	Postâ€“13-Valent Pneumococcal Conjugate Vaccine Dynamics in Young Children of Serotypes Included in Candidate Extended-Spectrum Conjugate Vaccines. Emerging Infectious Diseases, 2021, 27, 150-160.	2.0	16
458	Factors associated with pneumococcal polysaccharide vaccination of the elderly in Spain: A cross-sectional study. Human Vaccines and Immunotherapeutics, 2016, 12, 1891-9.	1.4	24
459	Changes in the Nature and Severity of Invasive Pneumococcal Disease in Children Before and After the Seven-valent and Thirteen-valent Pneumococcal Conjugate Vaccine Programs in Calgary, Canada. Pediatric Infectious Disease Journal, 2018, 37, 22-27.	1.1	20
460	A Phase 1 Randomized, Placebo-controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of Inactivated Streptococcus pneumoniae Whole-cell Vaccine in Adults. Pediatric Infectious Disease Journal, 2020, 39, 345-351.	1.1	19

#	Article	IF	Citations
461	COVID-19 vaccine development: a pediatric perspective. Current Opinion in Pediatrics, 2021, 33, 144-151.	1.0	76
462	Genetic profiles and antimicrobial resistance of Streptococcus pneumoniae non-PCV10 serotype isolates recovered from meningitis cases in Salvador, Brazil. Journal of Medical Microbiology, 2016, 65, 1164-1170.	0.7	9
463	Pneumococcal vaccine impacts on the population genomics of non-typeable Haemophilus influenzae. Microbial Genomics, 2018, 4, .	1.0	12
464	Population genomics of pneumococcal carriage in Massachusetts children following introduction of PCV-13. Microbial Genomics, 2019, 5, .	1.0	12
469	Recent advances in the epidemiology and prevention of Streptococcus pneumoniae infections. F1000Research, 2020, 9, 338.	0.8	37
470	Epidemiology, virulence factors and management of the pneumococcus. F1000Research, 2016, 5, 2320.	0.8	45
471	Serotypes and Clonal Diversity of Streptococcus pneumoniae Causing Invasive Disease in the Era of PCV13 in Catalonia, Spain. PLoS ONE, 2016, 11, e0151125.	1.1	30
472	Effect of the different 13-valent pneumococcal conjugate vaccination uptakes on the invasive pneumococcal disease in children: Analysis of a hospital-based and population-based surveillance study in Madrid, Spain, 2007-2015. PLoS ONE, 2017, 12, e0172222.	1.1	26
473	Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis. PLoS ONE, 2017, 12, e0177113.	1.1	279
474	Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea. PLoS ONE, 2017, 12, e0177342.	1.1	25
475	Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies. PLoS ONE, 2017, 12, e0177985.	1.1	69
476	Trends of vaccine-preventable diseases in Afghanistan from the Disease Early Warning System, 2009â€“2015. PLoS ONE, 2017, 12, e0178677.	1.1	16
477	Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study. PLoS ONE, 2017, 12, e0183191.	1.1	63
478	Increased carriage of non-vaccine serotypes with low invasive disease potential four years after switching to the 10-valent pneumococcal conjugate vaccine in The Netherlands. PLoS ONE, 2018, 13, e0194823.	1.1	45
479	Summary of Notifiable Infectious Diseases and Conditions â€" United States, 2015. Morbidity and Mortality Weekly Report, 2017, 64, 1-143.	9.0	126
480	Vital Signs: Epidemiology of Sepsis: Prevalence of Health Care Factors and Opportunities for Prevention. Morbidity and Mortality Weekly Report, 2016, 65, 864-869.	9.0	113
481	Direct, indirect and total effects of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children in Navarra, Spain, 2001 to 2014: cohort and caseâ€“control study. Eurosurveillance, 2016, 21, .	3.9	26
482	The Saudi Thoracic Society pneumococcal vaccination guidelines-2016. Annals of Thoracic Medicine, 2016, 11, 93-102.	0.7	23

#	Article	IF	Citations
483	Matching-adjusted indirect comparison of pneumococcal vaccines V114 and PCV20. Expert Review of Vaccines, 2022, 21, 115-123.	2.0	7
484	Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Greenland. Vaccines, 2021, 9, 1123.	2.1	1
485	Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age. Infectious Diseases and Therapy, 2021, 10, 2701-2720.	1.8	11
489	Immunisation. , 2019, , 19-169.		0
491	Invasive Pneumococcal Disease in Children Before and After the Introduction of Pneumococcal Conjugate Vaccine at a Regional Center in Kobe, Japan, 2002-2018. Journal of the Japanese Association for Infectious Diseases, 2019, 93, 485-492.	0.0	0
492	Impact and effectiveness of a conjugate vaccine against invasive pneumococcal disease in Finland - a modelling approach. Human Vaccines and Immunotherapeutics, 2021, 17, 1834-1843.	1.4	1
493	Study of Pneumococcal Surface Protein, PspA, Incorporated in Poly(Vinyl Alcohol) Hydrogel Membranes. Journal of Biomaterials and Nanobiotechnology, 2020, 11, 67-81.	1.0	1
494	VacunaciÃ³n frente a la enfermedad neumocÃ³cica con vacunas conjugadas: Â¿quÃ© es lo que verdaderamente importa?. Vacunas, 2020, 21, 23-40.	1.1	0
495	Immunological and Epidemiological Aspects of the Immunogenicity of Streptococcus Pneumoniae Serotype 3 Capsular Polysaccharide in Pneumococcal Vaccines. Zhurnal Mikrobiologii Epidemiologii I Immunobiologii, 2020, , 72-82.	0.3	0
496	Immunological and Epidemiological Aspects of the Immunogenicity of Streptococcus Pneumoniae Serotype 3 Capsular Polysaccharide in Pneumococcal Vaccines. Zhurnal Mikrobiologii Epidemiologii I Immunobiologii, 2020, 97, 72-82.	0.3	1
498	Epidemiology of non-vaccine serotypes of Streptococcus pneumoniae before and after universal administration of pneumococcal conjugate vaccines. Human Vaccines and Immunotherapeutics, 2024, 17, 5628-5637.	1.4	16
500	A Call for Greater Consideration for the Role of Vaccines in National Strategies to Combat Antibiotic-Resistant Bacteria: Recommendations from the National Vaccine Advisory Committee: Approved by the National Vaccine Advisory Committee on June 10, 2015. Public Health Reports, 2016, 131, 11-6.	1.3	8
501	The Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Seven Chinese Cities. Vaccines, 2021, 9, 1368.	2.1	2
502	Recent Topics of Pneumococcal Vaccination: Indication of Pneumococcal Vaccine for Individuals at a Risk of Pneumococcal Disease in Adults. Microorganisms, 2021, 9, 2342.	1.6	2
503	A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults â‰¥65 years of age with different prior pneumococcal vaccination. Vaccine, 2021, 39, 7494-7502.	1.7	33
504	Invasive Streptococcus pneumoniae isolates from pediatric population in Argentina for the period 2006â€“2019. Temporal progression of serotypes distribution and antibiotic resistance. Vaccine, 2022, 40, 459-470.	1.7	13
505	Influence of pneumococcal conjugate vaccine 13 on upper respiratory tract microbial biodiversity in infants. Biodiversitas, 2021, 22, .	0.2	0
506	Evaluation of the indirect impact of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine in a cluster-randomised trial. PLoS ONE, 2022, 17, e0261750.	1.1	0

#	Article	IF	Citations
507	Impact of 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease Among Adults with HIV â€" United States, 2008â€"2018. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, Publish Ahead of Print, 6-14.	0.9	2
508	A cluster-randomised, non-inferiority trial of the impact of a two-dose compared to three-dose schedule of pneumococcal conjugate vaccination in rural Gambia: the PVS trial. Trials, 2022, 23, 71.	0.7	7
509	Intra-Species Interactions in Streptococcus pneumoniae Biofilms. Frontiers in Cellular and Infection Microbiology, 2021, 11, 803286.	1.8	7
510	PCV-15 and PPSV-23 coverage of invasive and respiratory tract Streptococcus pneumoniae, including MDR and XDR isolates: CANWARD 2007â€"20. Journal of Antimicrobial Chemotherapy, 2022, 77, 1444-1451.	1.3	2
511	Estimates of the Health and Economic Burden of Pneumococcal Infections Attributable to the 15-Valent Pneumococcal Conjugate Vaccine Serotypes in the USA. Infectious Diseases and Therapy, 2022, 11, 987-999.	1.8	5
512	Non-invasive pneumococcal pneumonia due to vaccine serotypes: A systematic review and meta-analysis. EClinicalMedicine, 2022, 44, 101271.	3.2	13
513	Invasive Pneumococcal Disease Clusters Disproportionally Impact Persons Experiencing Homelessness, Injecting Drug Users, and the Western United States. Journal of Infectious Diseases, 2022, 226, 332-341.	1.9	3
514	Improving Pneumococcal Vaccination Rates in High-risk Children in Specialty Clinics. Pediatrics, 2022, 149, .	1.0	0
515	Population structure of ocular Streptococcus pneumoniae is highly diverse and formed by lineages that escape current vaccines. Microbial Genomics, 2022, 8, .	1.0	3
516	Determination of Streptococcus pneumonia Serotypes Isolated from Clinical Specimens: A Step Toward the Production of a Native Vaccine in Iran. Archives of Clinical Infectious Diseases, 2022, 16, .	0.1	2
517	Cost-effectiveness of the 15-valent pneumococcal conjugate vaccine for high-risk adults in Switzerland. Expert Review of Vaccines, 2022, 21, 711-722.	2.0	1
518	Serotypes and Clonal Composition of Streptococcus pneumoniae Isolates Causing IPD in Children and Adults in Catalonia before 2013 to 2015 and after 2017 to 2019 Systematic Introduction of PCV13. Microbiology Spectrum, 2021, 9, e0115021.	1.2	8
519	Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18â€"49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY). Open Forum Infectious Diseases, 2022, 9, ofab605.	0.4	9
520	Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged â‰¥18 Years. Clinical Infectious Diseases, 2022, 75, 390-398.	2.9	60
521	Incidence rates, emerging serotypes and genotypes, and antimicrobial susceptibility of pneumococcal disease in Taiwan: A multi-center clinical microbiological study after PCV13 implementation. Journal of Infection, 2022, 84, 788-794.	1.7	3
543	Efficacy assessment of a novel endolysin PlyAZ3aT for the treatment of ceftriaxone-resistant pneumococcal meningitis in an infant rat model. PLoS ONE, 2022, 17, e0266928.	1.1	0
544	Impact of Pneumococcal Conjugate Vaccines on Antibiotic-Nonsusceptible Invasive Pneumococcal Disease in the United States. Journal of Infectious Diseases, 2022, 226, 342-351.	1.9	14
545	Dynamic changes in clinical characteristics and serotype distribution of invasive pneumococcal disease among adults in Japan after introduction of the pediatric 13-valent pneumococcal conjugate vaccine in 2013â€"2019. Vaccine, 2022, 40, 3338-3344.	1.7	7

#	Article	IF	Citations
546	Impact of Pneumococcal Vaccination on Nasopharyngeal Carriage of Streptococcus pneumoniae and Microbiota Profiles in Preschool Children in South East Poland. Vaccines, 2022, 10, 791.	2.1	5
547	Membrane particles evoke a serotype-independent cross-protection against pneumococcal infection that is dependent on the conserved lipoproteins MalX and PrsA. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	7
548	Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States. Vaccine, 2022, 40, 4700-4708.	1.7	20
549	20-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults. Drugs, 2022, 82, 989-999.	4.9	7
550	Distribution of Serotypes Causing Invasive Pneumococcal Disease in Children From High-Income Countries and the Impact of Pediatric Pneumococcal Vaccination. Clinical Infectious Diseases, 2023, 76, e1062-e1070.	2.9	16
551	Pneumococcal vaccinationâ€"A literature review and practice guideline update. Pharmacotherapy, 2022, 42, 724-740.	1.2	9
552	An Experimental Human Colonization Model with Pneumococcal Serotype 3 has the Potential to be Used for Vaccine Studies. American Journal of Respiratory and Critical Care Medicine, 0, , .	2.5	0
553	Changes in serotype prevalence of Streptococcus pneumoniae in Southampton, UK between 2006 and 2018. Scientific Reports, 2022, 12, .	1.6	15
554	Pneumococcal meningitis in Greece: A retrospective serotype surveillance study in the post-PCV13 era (2010â€"2020). Vaccine, 2022, 40, 5079-5087.	1.7	3
555	Characterization of Emerging Serotype 19A Pneumococcal Strains in Invasive Disease and Carriage, Belgium. Emerging Infectious Diseases, 2022, 28, 1606-1614.	2.0	5
556	Predicting effectiveness of the V114 vaccine against invasive pneumococcal disease in children. Expert Review of Vaccines, 2022, 21, 1515-1521.	2.0	4
557	A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN). Vaccine, 2022, 40, 6315-6325.	1.7	6
558	Long-term population impact of infant 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in adults in Finland. Vaccine, 2022, 40, 5950-5958.	1.7	0
559	Safety of the 15-valent pneumococcal conjugate vaccine: A phase I clinical trial. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	0
560	Incidence of invasive pneumococcal disease in children with commercial insurance or Medicaid coverage in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998â€"2018. BMC Public Health, 2022, 22, .	1.2	3
561	Cost-utility and cost-benefit analysis of pediatric PCV programs in Egypt. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	0
562	Pathogenesis of Streptococcus pneumoniae serotype 3 during natural colonization and infections among children and its IgG correlate of protection in a mouse model. Vaccine, 2022, 40, 6412-6421.	1.7	2
563	Impact of rotavirus vaccination on diarrheal hospitalizations in children younger than 5Âyears of age in a rural southern Mozambique. Vaccine, 2022, 40, 6422-6430.	1.7	2

#	Article	IF	Citations
565	Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study. Blood Advances, 2023, 7, 414-421.	2.5	5
566	Kawasaki Disease Following the 13-valent Pneumococcal Conjugate Vaccine and Rotavirus Vaccines. Pediatrics, 2022, 150, .	1.0	4
567	Real world impact of 13vPCV in preventing invasive pneumococcal pneumonia in Australian children: A national study. Vaccine, 2022, , .	1.7	0
568	Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	1
569	Changing Trends of Invasive Pneumococcal Disease in the Era of Conjugate Pneumococcal Vaccination in Olmsted County: A Population-Based Study. Mayo Clinic Proceedings, 2022, 97, 2304-2313.	1.4	2
570	Clinical and economic burden of pneumococcal disease among individuals aged 16 years and older in Germany. Epidemiology and Infection, 2022, 150, .	1.0	4
571	Streptococcus pneumoniae. , 2023, , 753-762.e5.		0
572	Acute Pneumonia and Its Complications. , 2023, , 243-255.e4.		0
573	Active Immunization. , 2023, , 44-72.e5.		0
574	Infections Associated With Group Childcare. , 2023, , 24-32.e4.		0
575	Fever Without Localizing Signs. , 2023, , 120-122.e2.		0
577	Nasopharyngeal Carriage of Streptococcus pneumoniae Serotypes Among Healthy Children in Northern India. Current Microbiology, 2023, 80, .	1.0	1
578	Association of Pneumococcal Conjugate Vaccine Use With Hospitalized Pneumonia in Medicare Beneficiaries 65 Years or Older With and Without Medical Conditions, 2014 to 2017. JAMA Internal Medicine, 2023, 183, 40.	2.6	12
579	A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION). Vaccine, 2023, 41, 657-665.	1.7	6
580	A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED). Vaccine, 2023, 41, 1142-1152.	1.7	13
581	Cost-Effectiveness Analysis of Routine Use of 15-Valent Pneumococcal Conjugate Vaccine in the US Pediatric Population. Vaccines, 2023, 11, 135.	2.1	3
582	Frequent Transmission of Streptococcus pneumoniae Serotype 35B and 35D, Clonal Complex 558 Lineage, across Continents and the Formation of Multiple Clades in Japan. Antimicrobial Agents and Chemotherapy, 2023, 67, .	1.4	2
583	Involvement of the Streptococcus mutans PgfE and GalE 4-epimerases in protein glycosylation, carbon metabolism and cell division. Glycobiology, 0, , .	1.3	4

#	Article	IF	Citations
584	Strengths and weaknesses of pneumococcal conjugate vaccines. Glycoconjugate Journal, 2023, 40, 135-148.	1.4	12
586	Vaccine effectiveness of the pneumococcal polysaccharide and conjugated vaccines in elderly and high-risk populations in preventing invasive pneumococcal disease: a systematic search and meta-analysis. European Clinical Respiratory Journal, 2023, 10, .	0.7	2
588	Vaccines: An overview. , 2023, , 699-717.		1
589	Peptide linker increased the stability of pneumococcal fusion protein vaccine candidate. Frontiers in Bioengineering and Biotechnology, 0, 11, .	2.0	8
590	The dynamic change of serotype distribution and antimicrobial resistance of pneumococcal isolates since PCV13 administration and COVID-19 control in Urumqi, China. Frontiers in Cellular and Infection Microbiology, 0, 13, .	1.8	0
591	Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18â€“49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors. Human Vaccines and Immunotherapeutics, 2023, 19, .	1.4	4
592	Hearing outcomes in children with pneumococcal meningitis in the PCV13 era. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2023, 44, 103886.	0.6	1
593	A cost-effectiveness analysis of pneumococcal conjugate vaccines in infants and herd protection in older adults in Colombia. Expert Review of Vaccines, 2023, 22, 216-225.	2.0	2
594	Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine coadministered with quadrivalent influenza vaccine: A phase 3 randomized trial. Vaccine, 2023, 41, 2137-2146.	1.7	6
596	Comparative genomic epidemiology of serotype 3 IPD and carriage isolates from Southampton, UK between 2005 and 2017. Microbial Genomics, 2023, 9, .	1.0	0
597	Risk factors and pathogen characteristics associated with unfavorable outcomes among adults with pneumococcal meningitis in Japan, 2006 to 2016. Journal of Infection and Chemotherapy, 2023, , .	0.8	0
598	A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV. Aids, 2023, 37, 1227-1237.	1.0	3
599	Serotypes and Antibiotic Resistance of Streptococcus pneumoniae before and after the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine for Adults and Children in a Rural Area in Japan. Pathogens, 2023, 12, 493.	1.2	0
600	êµë‚´ ì†Œì•„ì—ì„œ íë ´êµ¬ê· ì˜ í˜ˆì²í˜• ë¶„í¬ ë³€í™”ì™€ í•ìƒì œ ë‚´ì„±, 2018â€“2022ë…„. , 2023, 16, 305-320.		0
601	Public health impact and cost-effectiveness of 15-valent pneumococcal conjugate vaccine use among the pediatric population of the United States. Vaccine, 2023, 41, 2914-2921.	1.7	3
602	Comparative genomic analysis of two ST320 Streptococcus pneumoniae isolates, representing serotypes 19A and 19F. BMC Genomic Data, 2023, 24, .	0.7	1
610	Vaccines and Immunization. , 2023, , 155-179.		0
612	Applications of synthetic biology in medical and pharmaceutical fields. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	17

#	Article	IF	Citations
616	Pneumococcal Polysaccharide Vaccines. , 2023, , 869-889.e12.		0
617	Pneumococcal Conjugate Vaccine and Pneumococcal Common Protein Vaccines. , 2023, , 826-868.e18.		0
625	Pneumococcal Meningitis in Children and Hearing Loss. , 2023, , 421-441.		0
629	Streptococcus pneumoniae. , 2024, , 1479-1490.		0